{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:27:31Z","timestamp":1792268851680,"version":"4.4.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,18]]},"DOI":"10.1093\/cid\/ciz089","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T05:54:14Z","timestamp":1548482054000},"page":"1-11","source":"Crossref","is-referenced-by-count":141,"title":["The Infectious Diseases Society of America\u2019s 10 \u00d7 \u201920 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 \u00d7 \u201920 a Possibility?"],"prefix":"10.1093","volume":"69","author":[{"given":"George H","family":"Talbot","sequence":"first","affiliation":[{"name":"Talbot Advisors LLC, Anna Maria, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Jezek","sequence":"additional","affiliation":[{"name":"Infectious Diseases Society of America, Arlington, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara E","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, McGovern Medical School at the University of Texas Health Science Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H","family":"Ebright","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Waksman Institute, Rutgers University, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J","family":"Nau","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Alpert Medical School at Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A","family":"Rodvold","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G","family":"Newland","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Washington University, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen W","family":"Boucher","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Infectious Diseases Society of America","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"2019061801002143400_CIT0001","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"2019061801002143400_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0003","author":"Centers for Disease Control and Prevention"},{"key":"2019061801002143400_CIT0004","unstructured":"World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. 2017. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/258965\/1\/WHO-EMP-IAU-2017.11-eng.pdf. Accessed 8 December 2017."},{"key":"2019061801002143400_CIT0005","unstructured":"Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Available at: http:\/\/www.idsociety.org\/uploadedFiles\/IDSA\/Policy_and_Advocacy\/Current_Topics_and_Issues\/Antimicrobial_Resistance\/10\u00d720\/Images\/Bad%20Bugs%20no%20Drugs.pdf. Accessed 5 June 2018."},{"key":"2019061801002143400_CIT0006","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/652237","article-title":"The 10 \u00d7 \u201920 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020","volume":"50","author":"Infectious Diseases Society of America","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0007","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 \u00d7 \u201920 Progress\u2013development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0008","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0009","unstructured":"Cidara Therapeutics. Cidara Therapeutics reports positive topline results from phase 2 STRIVE trial of lead antifungal rezafungin. Press release: Mar 18 2018. Available at: http:\/\/ir.cidara.com\/phoenix.zhtml?c=253962&p=irol-newsArticle&ID=2338634. Accessed 20 March 2018."},{"key":"2019061801002143400_CIT0010","unstructured":"Buil JB , RijsAJMM, MeisJFM, et al Activity of F901318 against azole-resistant and difficult-to-treat Aspergillus species. In: 26th European Congress of Clinical Microbiology and Infectious Diseases; 9\u201312 April 2016; Amsterdam, the Netherlands."},{"key":"2019061801002143400_CIT0011","doi-asserted-by":"crossref","first-page":"e01102","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2019061801002143400_CIT0013","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0014","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"2019061801002143400_CIT0015","doi-asserted-by":"crossref","first-page":"e00468","DOI":"10.1128\/AAC.00468-17","article-title":"Gepotidacin (GSK2140944) in vitro activity against gram-positive and gram-negative bacteria","volume":"61","author":"Flamm","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0016","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013\u20132016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb Drug Resist"},{"key":"2019061801002143400_CIT0017","doi-asserted-by":"crossref","unstructured":"Shortridge D , CastanheiraM, PfallerMA, StreitJM, FlammRK. Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2014\u20132016) Pseudomonas aeruginosa isolates with various resistant phenotypes from US hospitals. In: ASM Microbe; 1\u20135 June 2017; New Orleans, LA.","DOI":"10.1093\/ofid\/ofx163.912"},{"key":"2019061801002143400_CIT0018","author":"Merck & Co"},{"key":"2019061801002143400_CIT0019","doi-asserted-by":"crossref","first-page":"e01045","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2019061801002143400_CIT0021","doi-asserted-by":"crossref","first-page":"e01443","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0022","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"2019061801002143400_CIT0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2019061801002143400_CIT0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01856-17","article-title":"Antimicrobial activity of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0025","doi-asserted-by":"crossref","first-page":"e00472","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0026","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019061801002143400_CIT0027","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0028","doi-asserted-by":"crossref","unstructured":"Dunne M , DunzoE, PuttaguntaS. A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270). In: IDWeek; 4\u20138 October 2017; San Diego, CA.","DOI":"10.1093\/ofid\/ofx163.1369"},{"key":"2019061801002143400_CIT0029","doi-asserted-by":"crossref","first-page":"e00313","DOI":"10.1128\/AAC.00313-18","article-title":"In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from United States hospitals and comparative activity of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2017.11.004","article-title":"Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers","volume":"90","author":"Martins","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019061801002143400_CIT0031","doi-asserted-by":"crossref","unstructured":"Cloutier D , MillerL, KomirenkoA, et al Evaluating once-daily plazomicin versus meropenem for the treatment of complicated urinary tract infection and acute pyelonephritis: results from a phase 3 study (EPIC). In: ASM Microbe; 1\u20135 June 2017; New Orleans, LA.","DOI":"10.1093\/ofid\/ofx163.1385"},{"key":"2019061801002143400_CIT0032","doi-asserted-by":"crossref","unstructured":"Cloutier DJ , KomirenkoAS, CebrikDS, et al Plazomicin versus meropenem for complicated urinary tract infection and acute pyelonephritis: diagnosis-specific results from the phase 3 EPIC study. Poster abstract #1855. In: IDWeek;4\u20138 October 2017; San Diego, CA.","DOI":"10.1093\/ofid\/ofx163.1385"},{"key":"2019061801002143400_CIT0033","unstructured":"Connolly LE , JubbAM, O\u2019KeeffeB, et al Plazomicin is associated with improved survival and safety compared to colistin in serious carbapenem-resistant Enterobacteriaceae (CRE) infections: results of the CARE study. In: ASM Microbe; 1\u20135 June 2017; New Orleans, LA."},{"key":"2019061801002143400_CIT0034","unstructured":"Achaogen. ZEMDRI\u2122 (plazomicin) approved by FDA for the treatment of adults with complicated urinary tract infections (cUTI). Press release: June 26, 2018. Available at: http:\/\/investors.achaogen.com\/news-releases\/news-release-details\/update-zemdritm-plazomicin-approved-fda-treatment-adults. Accessed 5 September 2018."},{"key":"2019061801002143400_CIT0035","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0036","author":"Tetraphase Pharmaceuticals"},{"key":"2019061801002143400_CIT0037","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections","author":"Solomkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0038","author":"Tetraphase Pharmaceuticals"},{"key":"2019061801002143400_CIT0039","doi-asserted-by":"crossref","unstructured":"Kaye KS , RiceLB, DaneA, et al Intravenous fosfomycin (ZTI-01) for the treatment of complicated urinary tract infections (cUTI) including acute pyelonephritis (AP): results from a multi-center, randomized, double-blind phase 2\/3 study in hospitalized adults (ZEUS). In: Poster 1845. IDWeek; 4\u20138 October 2017; San Diego CA.","DOI":"10.1093\/ofid\/ofx163.1375"},{"key":"2019061801002143400_CIT0040","unstructured":"Shortridge D , FlammRK, RhombergPR, Ellis-GrosseEJ, SaderHS. Fosfomycin in vitro activity against bacteria with various mechanisms of resistance to other antibacterials from US hospitals. In: ASM Microbe; 1\u20135 June 2017; New Orleans, LA."},{"key":"2019061801002143400_CIT0041","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0042","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of cefiderocol (S-649266) against carbapenem-resistant gram-negative bacteria collected from inpatients in Greek hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019061801002143400_CIT0043","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant gram-negative pathogens","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019061801002143400_CIT0044","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01695-15","article-title":"In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains","volume":"60","author":"Kohira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0045","doi-asserted-by":"crossref","unstructured":"Portsmouth S , VeenhuyzenD, EcholsR, et al Clinical response of cefiderocol compared with imipenem\/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicenter, double-blind, randomized study (APEKS-cUTI). In: IDWeek; 4\u20138 October 2017; San Diego, CA.","DOI":"10.1093\/ofid\/ofx163.1399"},{"key":"2019061801002143400_CIT0046","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3390\/pathogens4030620","article-title":"In vitro activity of cefepime\/AAI101 and comparators against cefepime non-susceptible Enterobacteriaceae","volume":"4","author":"Crandon","year":"2015","journal-title":"Pathogens"},{"key":"2019061801002143400_CIT0047","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","article-title":"Murepavadin: a new antibiotic class in the pipeline","volume":"16","author":"Martin-Loeches","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2019061801002143400_CIT0048","unstructured":"Hackel M , BouchillonS, deJongeB, et al Global surveillance of the activity of sulbactam combined with the novel \u03b2-lactamase inhibitor ETX2514 against clinical isolates of Acinetobacter baumannii from 2014. In: IDWeek; 26\u201330 October 2016; New Orleans, LA."},{"key":"2019061801002143400_CIT0049","author":"Paratek"},{"key":"2019061801002143400_CIT0050","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"key":"2019061801002143400_CIT0051","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/AAC.02106-12","article-title":"A phase II clinical study of BC-3781, a pleuromutilin antibiotic, in the treatment of patients with acute bacterial skin and skin structure infection","volume":"57","author":"Prince","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019061801002143400_CIT0052","doi-asserted-by":"crossref","unstructured":"File T , GoldbergL, DasA, et al Lefamulin is non-inferior to moxifloxacin in adults with community-acquired bacterial pneumonia (CABP): the phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study. In: European Congress of Clinical Microbiology and Infectious Diseases; 21\u201324 April 2018; Barcelona, Spain.","DOI":"10.1093\/ofid\/ofy210.2039"},{"key":"2019061801002143400_CIT0053"},{"key":"2019061801002143400_CIT0054","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotadicin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0055","author":"Motif Bio"},{"key":"2019061801002143400_CIT0056","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fmicb.2013.00392","article-title":"Novel \u03b2-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance","volume":"4","author":"Watkins","year":"2013","journal-title":"Front Microbiol"},{"key":"2019061801002143400_CIT0057","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1473-3099(15)00466-1","article-title":"Alternatives to antibiotics","volume":"16","author":"Czaplewski","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2019061801002143400_CIT0058","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/ja.2017.124","article-title":"Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps","volume":"70","author":"Simpkin","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2019061801002143400_CIT0059","author":"Carroll"},{"key":"2019061801002143400_CIT0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/infdis\/jix211","article-title":"White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs","volume":"216","author":"Boucher","year":"2017","journal-title":"J Infect Dis"},{"key":"2019061801002143400_CIT0061","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/cid\/cis566","article-title":"Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health","volume":"55","author":"Talbot","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","author":"Talbot","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0063","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/cix246","article-title":"Progress in the fight against multidrug-resistant bacteria 2005-2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance","volume":"65","author":"Rex","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0064","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1093\/cid\/cir153","article-title":"Combating antimicrobial resistance: policy recommendations to save lives","volume":"52","author":"Spellberg","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0065","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/M17-1678","article-title":"Proposed U.S. funding cuts threaten progress on antimicrobial resistance","volume":"167","author":"Boucher","year":"2017","journal-title":"Ann Intern Med"},{"key":"2019061801002143400_CIT0066","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrd.2017.213","article-title":"Preclinical antibiotic pipeline gets a pick-me-up","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2019061801002143400_CIT0067","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/ciw217","article-title":"Executive summary: implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019061801002143400_CIT0068","author":"US Food and Drug Administration"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz089\/28556340\/ciz089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/1\/1\/28836015\/ciz089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:22:22Z","timestamp":1662855742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/1\/1\/5305275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2,1]]},"published-print":{"date-parts":[[2019,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz089","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,1]]},"published":{"date-parts":[[2019,2,1]]}}}